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Abstract 
circNOL10 is a circular RNA expressed at low levels in lung cancer, though its functions in lung cancer 
remain unknown. Here, the function and molecular mechanism of circNOL10 in lung cancer development 
are investigated using in vitro and in vivo studies, and it is shown that circNOL10 significantly inhibits the 
development of lung cancer and that circNOL10 expression is co‐regulated by methylation of its parental 
gene Pre‐NOL10 and by splicing factor epithelial splicing regulatory protein 1 (ESRP1). circNOL10 
promotes the expression of transcription factor sex comb on midleg‐like 1 (SCML1) by inhibiting 
transcription factor ubiquitination and thus also affects regulation of the humanin (HN) polypeptide family 
by SCML1. circNOL10 also affects mitochondrial function through regulating the humanin polypeptide 
family and affecting multiple signaling pathways, ultimately inhibiting cell proliferation and cell cycle 
progression, and promoting the apoptosis of lung cancer cells, thereby inhibiting lung cancer 
development. This study investigates the functions and molecular mechanisms of circNOL10 in the 
development of lung cancer and reveals its involvement in the transcriptional regulation of the HN 
polypeptide family by SCML1. The results also demonstrate the inhibitory effect of HN on lung cancer 
cells growth. These findings may identify novel targets for the molecular therapy of lung cancer. 
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1. Introduction
Lung cancer is the main cause of cancer-
related deaths worldwide, and has thus 
been a focus of cancer research.[1] Under-
standing the molecular mechanisms 
involved in lung cancer development 
is therefore critical for determining 
its therapy and prognosis. Increasing 
evidence suggests the existence of a close 
association between epigenetics and lung 
cancer. However, related studies have 
mainly concentrated on DNA methylation 
and histone modification,[2–4] and the roles 
of noncoding RNAs in lung cancer remain 
uncertain. However, we and others have 
investigated the association between non-
coding RNAs and lung cancer and con-
firmed an important regulatory function 
for noncoding RNAs in epigenetics and 
lung cancer development.[5–7]
Increasing numbers of types of non-
coding RNAs with different functions 
have been identified in recent studies, 
and circular RNAs (circRNAs), which represent a new type 
of noncoding RNAs, have become a recent topic of research. 
circRNAs are abundant in the human transcriptome and have 
diverse biological functions associated with their specific struc-
tural features.[8,9] circRNAs have high stability and show tissue-
specific expression patterns, and are known to be involved in 
cellular differentiation and pluripotency.[10–13] However, the 
functions of most of the thousands of unique circRNAs discov-
ered to date remain unknown. According to previous reports, 
most circRNAs are noncoding RNAs, although a few protein-
coding circRNAs have recently been reported.[14,15] circRNAs 
have diverse functions and mechanisms of biogenesis, and 
have been implicated in many different cancers.[16] Previous 
studies have also shown close associations between circRNAs 
and lung cancer, though the specific mechanisms whereby cir-
cRNAs may affect carcinogenesis and lung cancer progression 
are largely unclear.[17,18]
We investigated the functions and molecular mechanisms 
of circRNAs in lung cancer in experimental studies. Using our 
high-throughput circRNA data (Table S1, Supporting Informa-
tion), we detected the expression of circRNAs in different lung 
cancer cell lines and in human lung cancer tissue samples, and 
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found that the circRNA circNOL10 (formed by circularization 
of 6–12 exons of Pre-NOL10; circBase ID: has_circ_0000977, 
alias has_circ_001918) was significantly downregulated in lung 
cancer. Furthermore, Pre-NOL10 methylation and the splicing 
factor epithelial splicing regulatory protein 1 (ESRP1) worked 
together to downregulate circNOL10 expression in lung cancer, 
associated with significant inhibition of lung cancer devel-
opment. circNOL10 was mainly located in the nucleus, and 
bioinformatics analysis revealed that it was involved in tran-
scriptional regulation, rather than protein coding. circNOL10 
promoted the expression of sex comb on midleg-like 1 (SCML1) 
by inhibiting its ubiquitination. Using chromatin immuno-
precipitation sequencing (ChIP-Seq) and other methods, we 
showed that SCML1 could regulate the humanin (HN) poly-
peptide family and that this SCML1-mediated transcription was 
promoted by circNOL10. In addition, circNOL10 affected mito-
chondrial function by promoting the expression of HN. This 
alteration in mitochondrial function triggered multiple sign-
aling pathways and ultimately inhibited cell proliferation and 
cell cycle progression and promoted apoptosis of lung cancer 
cells, thereby significantly inhibiting lung cancer progression.
Most current circRNA studies focus on the role of circRNAs 
as endogenous competitive RNAs.[19,20] In contrast, we pro-
vide the first evidence for a molecular mechanism whereby 
circRNAs may affect the transcriptional regulation of genes. 
We also explored the functions and mechanisms of circRNAs 
in lung cancer in relation to the HN polypeptide family. The 
results of this study reveal a new mechanism of lung cancer 
development and demonstrate the significance of epigenetics 
in lung cancer.
2. Results
2.1. circNOL10 Inhibited Lung Cancer Development
circNOL10 was shown to be a circRNA formed by cyclization 
of exons 6–12 of Pre-NOL10. A linear RNA (NOL10 mRNA) 
was also generated during the formation of circNOL10 (UCSC 
Genome Browser). Divergent primers spanning the backsplicing 
site were designed and used to detect circNOL10 expression 
(Figure 1A and Figure S1A,B, Supporting Information) in six 
lung cancer cell lines (A549, H1299, H226, H460, H661, and 
SK-MES-1) and in noncancerous bronchial epithelial BEAS-2B 
cells (control). circNOL10 expression levels were significantly 
decreased in all six lung cancer cell lines, and were lowest in 
H460 and A549 cells (decreased by 13-fold and 8-fold, respec-
tively) (Figure 1B). circNOL10 expression was also detected in 
61 pairs of cancerous and paracancerous lung tissue samples, 
and levels were shown to be significantly lower in the cancer 
tissues in 41 of the 61 paired samples (Figure S1C, Supporting 
Information). The decrease in circNOL10 expression in lung 
cancer compared with control tissues was statistically significant 
(Figure 1C). circNOL10 expression levels were also significantly 
lower in poorly and intermediately differentiated lung cancers, 
and the decreases in lung squamous cell carcinoma and lung 
adenocarcinoma tissues were both significant (Figure 1D,E).
We further examined the function of circNOL10 in cell lines 
in vitro by silencing its expression in H460 and A549 cells 
using three types of small interfering (si)RNAs. The silencing 
efficiencies of siRNA1 and siRNA2 were both more than twice 
that of the scrambled sequence, and also significantly higher 
than that of siRNA3 (Figure S1D, Supporting Information). A 
vector overexpressing circNOL10 was designed (Figure S1E, 
Supporting Information) and resulted in more than tenfold 
increases in expression levels in both H460 and A549 cells, 
compared with blank vector (vec) (Figure S1F, Supporting 
Information). We investigated the specificities of the silencing 
and overexpression (OE) experiments for circNOL10 and dem-
onstrated that the siRNAs and overexpression vector silenced 
and overexpressed circNOL10, respectively, in H460 and A549 
cells, while Pre-NOL10 and NOL10 mRNA levels were unaf-
fected (Figure S1G, Supporting Information).
H460 and A549 cells were transiently transfected with 
circNOL10 siRNA1 and siRNA2 to silence circNOL10 expres-
sion, and with circNOL10 OE vector to overexpress circNOL10 
for in vitro functional studies. Moreover, we analyzed 
circNOL10-sponged miRNA in relation to regulatory RNA 
motifs and elements (RegRNA; http://regrna.mbc.nctu.edu.tw/
index1.php) (Table S2, Supporting Information) and pathways 
(mirPath v.3; http://snf-515788.vm.okeanos.grnet.gr) (Table S3, 
Supporting Information), and revealed that circNOL10 was 
involved in multiple pathways associated with tumor devel-
opment (Figure 1F). We further examined the effects of 
circNOL10 on cellular behaviors or processes, including 
cell viability (Figure 1G), apoptosis (Figure 1H,I), prolifera-
tion (Figure 1J,K), cell cycle (Figure 1L,M and Figure S1H,I, 
Supporting Information), invasion (Figure 1N,O), migration 
(Figure 1P,Q), and adhesion (Figure 1R). Compared with trans-
fection with a scrambled sequence, transfection of H460 cells 
and A549 cells with circNOL10 siRNA1 or siRNA2 significantly 
increased cell viability, proliferation, invasion ability, migration, 
and adhesion, as well as the proportion of cells in S and G2/M 
phases, and significantly decreased the proportion of cells 
undergoing apoptosis and in G0/G1 phase. Cells transfected 
with circNOL10 OE showed opposite changes to those seen in 
the gene-silencing groups, compared with blank vector (vec).
We also explored the function of circNOL10 in vivo by subcu-
taneous injection into tumor-bearing nude mice. A green fluo-
rescent protein (GFP) tagged circNOL10 OE vector (Figure S1J, 
Supporting Information) and GFP-tagged blank vector were con-
structed and packaged in lentiviruses, and then stably transfected 
into the cell lines. Their overexpression efficiency was detected 
with quantitative polymerase chain reaction (qPCR). Compared 
with H460 cells stably transfected with blank vector (vec-ST) as 
a control, circNOL10 expression was increased 12-fold in cells 
stably transfected with overexpression vector (circNOL10 OE-ST) 
(Figure S1K, Supporting Information). We investigated the func-
tion of circNOL10 in nude mice with subcutaneous tumors 
using in vivo imaging (Figure 2A) to detect the fluorescence 
intensities (Figure 2B) and sizes of the subcutaneous tumors 
(Figure 2C). The tumors were then removed and observed at 21 d 
after injection of the transfected cells (Figure 2D). The fluo-
rescence intensities at different time points were significantly 
lower in the circNOL10 OE-ST group compared with the control 
vec-ST group, while tumors also appeared later in the circNOL10 
OE-ST compared with the vec-ST group. The tumors were solid, 
and tumors in the circNOL10 OE-ST group were significantly 
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Figure 1. Significant inhibitory effect of circNOL10 on lung cancer development in vitro. A) Pre-NOL10 is the parental gene of circNOL10, and 
NOL10 mRNA is the mature linear RNA. We designed PCR primers to span the back-splice junction to ensure the specificity of circNOL10 detection. 
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smaller than those in the vec-ST group. We created a mouse lung 
cancer xenograft model by injection of vec-ST and circNOL10 
OE-ST cells via the caudal vein (Figure 2E). The fluorescence 
intensities and tumor growth rates at different time points were 
significantly lower in the circNOL10 OE-ST compared with the 
vec-ST group, as shown with in vivo imaging (Figure 2F).
Hematoxylin and eosin (HE) staining of the subcutaneous 
tumors showed that the nuclear: cytoplasmic ratio and nuclear 
atypia were both reduced in the circNOL10 OE-ST compared 
with the control group, suggesting that circNOL10 overexpres-
sion reduced the degree of malignancy (Figure 2G). HE staining 
also revealed fewer lung-tumor foci in the circNOL10 OE-ST 
compared with the vec-ST group, and a lower degree of malig-
nancy (Figure 2H). We detected the expression levels of six 
tumor biomarkers by immunohistochemical assay. Expression 
levels of the proapoptotic protein Bax and caspase-9 were sig-
nificantly increased in the circNOL10 OE-ST group compared 
with the vec-ST group, while levels of the apoptosis-inhibitory 
protein Bcl-2 were significantly decreased. Furthermore, expres-
sion of the invasion-inhibitory marker E-cadherin and the 
tumor suppressor phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) were significantly increased, while the 
proliferation marker proliferating cell nuclear antigen (PCNA) 
was significantly decreased by circNOL10 overexpression 
(Figure 2I,J). This in vivo study thus confirmed the inhibitory 
effect of circNOL10 on tumor development.
2.2. Pre-NOL10 Methylation and Splicing Factor ESRP1 Coop-
eratively Inhibited circNOL10 Expression in Lung Cancer Cells
Given that downregulation of circNOL10 in lung cancer cells 
had a significant synergistic effect on lung cancer development, 
we investigated the reasons for this downregulation to improve 
our understanding of the functions and associated molecular 
mechanisms of circNOL10. Linear mature NOL10 mRNA and 
circNOL10 are both derived from the Pre-NOL10 gene. NOL10 
mRNA expression levels were reduced 1.8-fold and 2.4-fold 
in H460 and A549 cells, respectively, compared with noncan-
cerous BEAS-2B cells (Figure 3A), whereas circNOL10 levels 
were decreased 13-fold and 8-fold, respectively (Figure 1B). 
circNOL10 expression was thus reduced more significantly 
than NOL10 mRNA in lung cancer cells.
To clarify the regulatory mechanism of circNOL10 formation, 
we analyzed the genomic elements likely to affect circNOL10 
circularization, and then performed genomic sequencing of the 
flanking intron regions. There were a few mutation sites, but 
none in the circularization-associated elements (Figure S2A, 
Supporting Information). This suggested that low circNOL10 
expression in tumor cells was unlikely to be due to mutation of 
the NOL10 gene.
We designed RNA antisense purification (RAP) probes tar-
geting Pre-NOL10 and performed RAP assays to detect pro-
teins binding to Pre-NOL10. Silver staining showed numerous 
proteins interacting with Pre-NOL10. The molecular weights 
of most of the purified proteins were <25 kD (Figure 3B). 
The purified proteins were identified using mass spectrom-
etry (MS) and subjected to gene ontology (GO) analysis 
(http://www.geneontology.org). Pre-NOL10-binding proteins 
were shown to have important functions in RNA splicing 
(Figure 3C). Based on the MS results and on previous studies 
suggesting that RNA splicing factors can regulate the forma-
tion of specific circRNAs,[13] we identified ESRP1 as a typical 
splicing factor involved in the formation of circRNAs. In the 
current study, we therefore investigated the role of ESRP1 in 
circNOL10 formation. MS confirmed the expression of ESRP1 
protein (Figure 3D), and western blotting showed that ESRP1 
was significantly downregulated in A549 and H460 cells com-
pared with BEAS-2B cells (Figure 3E,F). Structural analysis of 
ESRP1 (http://smart.embl-heidelberg.de) showed that it com-
prised three monomers, the positions of which corresponded 
to the positions of the functional domain displayed in the sec-
ondary structure (Figure 3G). circNOL10 expression levels in 
the ESRP1 RNA immunoprecipitation (RIP) products of H460 
and A549 cells were higher than in BEAS-2B cells, as dem-
onstrated with RIP-PCR, indicating that ESRP1 had a higher 
binding capacity for circNOL10 in H460 and A549 cells than in 
BEAS-2B cells (Figure 3H,I). We silenced ESRP1 in H460 and 
A549 cells (Figure S2B, Supporting Information) using siRNA1 
and siRNA2 to clarify its effect on the formation of circNOL10 
and NOL10mRNA. circNOL10 and NOL10 mRNA levels 
were both significantly downregulated by silencing ESRP1 
(Figure 3J,K). In addition to splicing factors, RNA splicing is 
also regulated by m6A methylation.[21] We therefore analyzed 
the methylation sites in Pre-NOL10 (https://www.ncbi.nlm.
nih.gov/). We identified numerous RNA methylation sites 
in Pre-NOL10 and selected three in the exons near the cycli-
zation region for further study. We designed specific primers 
(Figure 3L) for N6-methyladenosine RIP PCR (m6A MeRIP-
PCR) and showed that the methylation levels of all three sites 
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B) circNOL10 in normal bronchial epithelial cells (BEAS-2B) and lung cancer cell lines (A549, H1299, H226, H460, H661, and SK-MES-1) by qPCR. 
Mean ± SD, n = 3; unpaired t-test, **P < 0.01. C) circNOL10 in tumor tissues and adjacent tissues by qPCR. Mean ± SD, n = 61; ANOVA, **P < 0.01. 
D) circNOL10 detection in poorly and moderately differentiated lung cancers using qPCR. Mean ± SD, n = 3; ANOVA, **P < 0.01. E) circNOL10 detec-
tion in adenocarcinoma and squamous cell carcinoma using qPCR. Mean ± SD, n = 3; ANOVA, **P < 0.01. F) circNOL10-sponged miRNA pathway 
analysis by OriginPro2016. The Y-axis indicates pathways; the X-axis indicates enrichment factor (ratio of differentially expressed genes enriched in the 
pathways to the number of annotated genes in the corresponding pathways); size of the point indicates the number of differentially expressed genes in 
the corresponding pathways (gene number); color of the point refers to the P value range. G) circNOL10 function in tumor cell viability detected with 
CCK8 assay. H,I) circNOL10 function in tumor cell apoptosis detected by flow cytometry (FCM). Cells stained with AnnexinV-fluorescein isothiocyanate 
(FITC) and propidium iodide (PI) for apoptosis detection. J,K) circNOL10 function in tumor cell proliferation detected by EdU assay. Nuclei were stained 
with DAPI. Combined reaction with EdU and DAPI indicated cells in S phase. L,M) circNOL10 function in tumor cell cycle detected with FCM. Cells 
stained with PI. Cell count indicates the number of cells in different cell cycle phases. N,O) circNOL10 function in tumor cell invasion detected with 
transwell assay. P,Q) circNOL10 function in tumor cell metastasis detected with scratch assay. R) circNOL10 function in tumor cell adhesion detected 
with adhesion assay. G,I,K,M,O,Q,R) Mean ± SD, n = 3; unpaired t-tests; compared with the scramble group, *P < 0.05, **P < 0.01; compared with 
the vec group, #P < 0.05, ##P < 0.01.
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Figure 2. Significant inhibitory effect of circNOL10 on lung cancer development in vivo. A) Nude mice injected subcutaneously with circNOL10 stable-
overexpression (circNOL10 OE-ST) or control cells (vec-ST). Subcutaneous tumor fluorescence intensities were detected in vivo using an in vivo small 
animal imaging system at 1, 3, 5, 7, 14, and 21 d, indicating tumor growth. B) Relative fluorescence intensities in subcutaneous tumor-bearing nude 
mice at 1, 3, 5, 7, 14, and 21 d. C) Tumor sizes in subcutaneous tumor-bearing nude mice at 1, 3, 5, 7, 14, and 21 d. D) Subcutaneous tumors removed 
from nude mice at 21 d. E) Nude mouse models were created by caudal vein injection of cells (circNOL10 OE-ST and vec-ST) and fluorescence intensi-
ties were detected in vivo at 1, 3, 5, 7, 14, and 21 d using a small animal imaging system. F) Relative fluorescence intensities in caudal vein injection 
nude mice at 1, 3, 5, 7, 14, and 21 d. G) HE staining of subcutaneous tumors at ×200 and ×400. H) HE staining of lung tissues at ×40 and ×400. 
I) Immunohistochemical assays of six tumor markers (Bax, Bcl-2, caspase-9, E-cadherin, PCNA, and PTEN) in subcutaneous tumors (×200). J) Quantita-
tive immunohistochemical analysis of six tumor markers. B,C,F) n = 3, mean ± SD; ANOVA, **P < 0.01. J) n = 3, mean ± SD; unpaired t-test, **P < 0.01.
www.advancedsciencenews.com
1800654 (6 of 16) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
Adv. Sci. 2019, 6, 1800654
Figure 3. Causal exploration of significant circNOL10 downregulation in lung cancer cells. A) N0L10 mRNA expression in BEAS-2B, H460, and A549 
cells determined by qPCR. B) Silver staining of purified interaction proteins in Pre-NOL10 RAP experiment. NC, scramble control group; RAP, protein 
group obtained by RNA antisense purification; and Input, total protein group. C) GO analysis of Pre-NOL10 RAP-MS results. Molecular function, cellular 
component, and biological process represent three aspects of GO analysis. Larger −log10 (P value) indicates more significant enrichment and more 
differentially expressed genes (No. of genes). GO analysis indicated that the interaction proteins were involved in multiple RNA splicing pathways. 
D) Mass spectrogram of ESRP1 protein. E,F) Semi-quantitative analysis of ESRP1 protein expression in BEAS-2B, H460, and A549 cells detected with 
western blot. G) ESRP1 protein domain analysis (http://smart.embl-heidelberg.de) (Q6NXG1 is an alias for ESRP1). Three monomer positions of 
ESRP1 are shown. RRM indicates the three functional domains in the ESRP1 protein secondary structure. H,I) ESRP1 RIP-PCR and RIP-qPCR results 
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were significantly increased in H460 and A549 cells compared 
with BEAS-2B cells (Figure 3M,N). RNA methylation is known 
to be a switch regulating RNA structure, and hypermethylation 
opens nucleic acid bonds and thus affects the formation of cir-
cRNAs rather than linear mRNAs.[22] We therefore supposed 
that hypermethylation of Pre-NOL10 in H460 and A549 cells 
inhibited the formation of circNOL10. Overall, these results 
suggested that the low circNOL10 expression levels relative to 
NOL10 mRNA in lung cancer cells may be a consequence of 
co-regulation by ESRP1 and Pre-NOL10 methylation (Figure 3O).
2.3. circNOL10 Directly Promoted Expression of the 
Transcription Factor SCML1 in Lung Cancer Cells
We further explored the molecular mechanism responsible 
for the inhibitory effect of circNOL10 in lung cancer develop-
ment by determining its subcellular localization in H460 and 
A549 cells with fluorescence in situ hybridization (FISH). 
circNOL10 was expressed in both the cytoplasm and nucleus, 
but levels were significantly higher in the nucleus (Figure 4A). 
Bioinformatics analysis of circNOL10 showed that it lacked an 
open reading frame, polyadenylation sites, ribosome-binding 
site, and an Rho-independent terminator, but included human 
splicing sites and a transcriptional regulatory motif (http://
www.jcat.de/Start.jsp;http://regrna2.mbc.nctu.edu.tw/detec-
tion_output.php). Some rare codons were found, and the rela-
tive adaptiveness of most codons was higher than the mean 
codon usage (red line, Figure 4B). Based on these data and 
its predominant expression in the nucleus, we considered 
that circNOL10 was unlikely to encode a protein and may be 
involved in transcriptional regulation.
We investigated transcriptional factors potentially regulated 
by circNOL10 by RNA pull-down assay of circNOL10-binding 
proteins followed by silver staining (Figure 4C). MS anal-
ysis identified one particularly abundant transcription factor 
(Figure S3A, Supporting Information) as SCML1 (Figure 4D). 
SCML1 was downregulated in lung cancer cells (H460 and 
A549) compared with control BEAS-2B cells, as shown by 
western blot (Figure 4E,F) and confirmed by immunocyto-
chemistry (Figure 4G,H).
We studied the interaction between circNOL10 and SCML1 
by luciferase reporter gene assay. We constructed SCML1-
silencing and overexpression vectors (Figure S3B,C, Supporting 
Information), and circNOL10 reporter gene vectors and co-
transfected them into lung cancer cells. Compared with cells 
transfected with scrambled sequences, relative fluorescence 
intensity was significantly increased in SCML1-silenced cells, 
and was significantly decreased by SCML1 overexpression 
(Figure 4I). These results suggested an association between 
circNOL10 and SCML1. To verify the direct interaction between 
circNOL10 and SCML1, we constructed a prokaryotic SCML1-
overexpression vector and obtained purified SCML1 protein 
(Figure S3D, Supporting Information). We then tested the 
direct interaction between circNOL10 and SCML1 by RNA elec-
trophoretic mobility shift assay (EMSA). A shifted band was 
detected in the SCML1 and circNOL10 EMSA probe group, but 
not in the circNOL10 or nonmutant probe groups (Figure 4J). 
This confirmed a direct interaction between circNOL10 and 
SCML1.
The interacting regions of circNOL10 and SCML1 were pre-
dicted using catRAPID tool (http://service.tartaglialab.com/
grant_submission/catrapid_graphic). The interaction propen-
sity was 86% and discriminative power was 98%, with two 
obvious binding regions, Binding1 (B1) and Binding2 (B2). 
Secondary structure analysis of circNOL10 (http://rna.urmc.
rochester.edu/RNAstructureWeb/) showed RNA functional 
domains in the B1 and B2 binding regions. Analysis of SCML1 
functional domains (http://smart.embl-heidelberg.de) showed 
amino acids 255–324 of SCML1 included a sterile alpha motif 
(SAM) domain, located in the binding regions predicted by 
catRAPID (Figure 4K). The full-length circNOL10 probe was 
truncated to three segments (Figure 4L), and the full-length 
and truncated probes were then used in RNA pull-down assays 
to identify the specific locations of the binding regions. RPD, 
RPD1, and RPD2 pulled down abundant proteins, but RPD3 
failed to pull down any proteins (Figure 4M). The proteins 
obtained by RNA pull-down were further detected and ana-
lyzed with western blot, which confirmed the positive results 
for RPD, RPD1, and RPD2, but negative results for RPD3 
(Figure 4N). These findings confirmed that circNOL10 inter-
acted with the SCML1 B1 and B2 regions.
We detected SCML1 expression in H460 cells after silencing 
or overexpression of circNOL10 by western blot, to inves-
tigate the regulatory interaction between circNOL10 and 
SCML1. SCML1 expression was increased by overexpres-
sion of circNOL10, and decreased by circNOL10 silencing 
(Figure 4O,P). circNOL10 overexpression was also associated 
with increased SCML1 expression and silencing of circNOL10 
with decreased SCML1 expression according to immunocyto-
chemistry (Figure 4Q,R). These results indicated circNOL10 
promoted SCML1 expression in lung cancer cells.
High levels of protein ubiquitination have been reported 
to accelerate their degradation, while RNAs can promote the 
expression of RNA-binding proteins by inhibiting protein 
ubiquitination.[23,24] To confirm if circNOL10 increased SCML1 
expression by inhibiting ubiquitination, we identified and 
analyzed the ubiquitination sites in SCML1 (http://bdmpub.
biocuckoo.org/prediction.php) (Figure S3E, Supporting Infor-
mation). We then silenced or overexpressed circNOL10 in 
H460 cells and performed SCML1 co-immunoprecipitation 
assays in BEAS-2B cells (Figure S3F, Supporting Informa-
tion). We detected SCML1 and ubiquitin with western blot and 
showed that the degree of SCML1 ubiquitination was signifi-
cantly higher in H460 compared with BEAS-2B cells. Together 
with the fact that SCML1 was downregulated in cancer cells, 
Adv. Sci. 2019, 6, 1800654
for circNOL10 and GAPDH in BEAS-2B, H460, and A549 cells. J) circNOL10 expression in H460 and A549 cells after silencing ESRP1, determined 
with qPCR. K) NOL10 mRNA expression in H460 and A549 cells after silencing ESRP1, determined by qPCR. L) Pre-NOL10 methylation site prediction 
and primer design for m6A MeRIP PCR. M,N) MeRIP-PCR and MeRIP-qPCR results of m6A in BEAS-2B, H460, and A549 cells. O) Causal diagram of 
downregulation of circNOL10 in lung cancer cells. A,F,I,J,K,N) n = 3, mean ± SD, unpaired t-test, **P < 0.01.
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Figure 4. Mechanism of circNOL10 in regulating transcription factor SCML1. A) Distribution of circNOL10 in H460 and A549 cells determined by 
FISH. circNOL10 group, using specific probe; DAPI staining indicates nuclei; merge represents an overlay figure. B) circNOL10 nucleic acid sequence 
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we hypothesized that ubiquitination was involved in regu-
lating the expression of SCML1 in lung cancer cells. Ubiquitin 
expression was significantly decreased by circNOL10 overex-
pression and increased by silencing circNOL10 (Figure 4S–U). 
All these results suggested that circNOL10 inhibited SCML1 
ubiquitination to increase its expression in lung cancer cells.
2.4. circNOL10 Promoted the Transcriptional Regulatory Effect 
of SCML1 on HN
We analyzed the tertiary structure of SCML1 and identified 
amino acids (aa) 251–321 as the region where monomer 
structures were formed, which corresponded with the func-
tional domain identified by secondary structure analysis (SAM 
domain: 255–324 aa) (Figure 4K and Figure 5A), indicating the 
potential role of SCML1 in transcriptional regulation. We per-
formed ChIP-Seq to detect potential genes regulated by SCML1 
(Figure S4A,B, Supporting Information). Kyoto encyclopedia 
of genes and genomes (KEGG) analysis of the identified genes 
showed that the genes regulated by SCML1 played roles in mul-
tiple pathways associated with cancer development (Figure 5B), 
while GO analysis also suggested that genes regulated by 
SCML1 had important roles in molecular function, cellular com-
ponents, and biological processes (Figure 5C).
ChIP-Seq analysis identified the HN polypeptide family as 
a group of genes potentially regulated by SCML1 (Figure S4C, 
Supporting Information). HN has a significant protective func-
tion in normal cells,[25,26] but its function and mechanism in 
lung cancer development is unknown. ChIP-PCR and ChIP-
qPCR indicated that SCML1 acted on multiple members of 
the HN polypeptide family, including HN1, HN2, HN3, HN5, 
HN6, HN8, HN9, and HN10, particularly HN2 and HN8. 
Furthermore, transcription levels of HN2 and HN8 were sig-
nificantly decreased in H460 and A549 cells compared with 
BEAS-2B cells (Figure 5D–I). circNOL10-targeting chromatin 
isolation by RNA purification (CHIRP)-PCR and CHIRP-qPCR 
further showed that H460 cells expressed all members of the 
HN family, with particularly high expression of HN1, HN2, 
and HN8 (Figure 5J,K). These findings suggest that circNOL10 
can modulate the transcriptional regulatory effect of SCML1 
on the HN polypeptide family. Considering the abundances of 
HN2 and HN8, we selected these two HN members for further 
experiments, as representatives of the HN family.
We investigated if SCML1 regulated HN transcription directly 
by SCML1 ChIP-Seq, and found little difference between HN2 
and HN8 sequences; two motifs (motif 1 and motif 2) in SCML1 
matched both HN2 and HN8 (Figure 5L,M). We analyzed the 
different regions of the HN2 and HN8 sequences and designed 
DNA EMSA probes targeting HN2, HN8, or HN2 plus HN8. 
We then determined if SCML1 acted directly on HN2 and/or 
HN8 by EMSA. A super-shifted band plus SCML1 band were 
only detected in nuclear extracts (Figure 5N–P), indicating a 
direct interaction between SCML1 and HN2 or HN8.
We further investigated the transcriptional regulation of HN 
by SCML1 by detecting HN2 and HN8 expression with qPCR 
after silencing and overexpressing SCML1 in H460 and A549 
cells. Silencing SCML1 resulted in a significant decrease in 
HN2 and HN8 expression levels, while SCML1 overexpression 
had the opposite effects (Figure 5Q). HN2 and HN8 expression 
levels were also reduced by silencing circNOL10 and increased 
by circNOL10 overexpression (Figure 5R). Given that low 
expression of circNOL10 inhibited SCML1 (Figure 4O,Q,R), we 
supposed that circNOL10 promoted the transcriptional regula-
tory effect of SCML1 on the HN polypeptide family.
2.5. circNOL10 Inhibited Lung Cancer Cell Growth  
by Regulating the HN Polypeptide Family
The HN polypeptide family shows high homology with the 
mitochondrial gene (MT-RNR-like), but its precise origin has 
not been elucidated.[27] We studied the subcellular localization 
of HN using HN2 and HN8 expression vectors with fluorescent 
flags, using Mito Tracker staining. Confocal laser microscopy 
indicated that HN2 and HN8 were largely fused, suggesting 
that they were both mainly distributed in the mitochondria 
(Figure 6A).
Changes in mitochondrial functions have a profound impact 
on tumor development.[28,29] HN2 and HN8 localization in the 
mitochondrion indicates that the HN family, as well as their reg-
ulator circNOL10, may play key roles in affecting mitochondrial 
function in lung cancer cells. We therefore explored the effects 
of HN and circNOL10 on mitochondrial function in lung cancer 
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indicating open reading frames (ORF), splice sites, polyadenylation sites (PAS), ribosome binding site (RBS), Rho-independent terminator (RIT), tran-
scriptional regulatory motif (TR motif), and codons. There were two splice sites and several transcriptional regulatory motifs. The structure suggested 
that circNOL10 was unlikely to encode a protein. C) Silver staining of proteins obtained by RNA pull-down (RPD). A specific probe against circNOL10 
was designed for RPD. Input group, total protein group; RPD group, pull-down group; NC, scramble control group. D) Mass spectrogram of SCML1 
protein. E,F) Semi-quantitative analysis of SCML1 protein expression in BEAS-2B, H460, and A549 cells detected with western blot. G,H) Quantitative 
analysis of SCML1 protein expression in BEAS-2B, H460, and A549 cells detected with immunocytochemistry assay. I) Construction of a dual luciferase 
reporter vector targeting circNOL10 and relative fluorescence intensity after SCML1 silencing or overexpression. J) Interaction between circNOL10 
and SCML1 detected by RNA-EMSA. Protein (SCML1), prokaryotically expressed SCML1 protein; probe (circNOL10), circNOL10-specific RNA EMSA 
probe; specific competitor, nonmutable competitive probe. K) Bioinformatics analysis of interaction region and intensity between circNOL10 and 
SCML1, and identification of domains and matched binding sites in relation to circNOL10 secondary structure analysis. SAM, SCML1 domain; B1, 
Binding1; B2, Binding2. L) Three truncated RPD probes and a specific RNA pull-down probe were designed to capture circNOL10-interacting proteins 
based on the matching sites. M) Silver staining of proteins obtained by RNA pull-down assay using circNOL10- specific RNA pull-down probe and 
three truncated probes. N) Qualitative analysis of SCML1 protein expression in RNA pull-down products with different probes, detected with western 
blot. O,P) Semi-quantitative analysis of SCML1 protein expression in H460 cells after circNOL10 silencing or overexpression, detected with western 
blot. Q,R) Quantitative analysis of SCML1 protein expression in H460 cells after circNOL10 silencing or overexpression, detected with ICC. 
S–U) Semi-quantitative analysis of SCML1 and ubiquitin protein co-immunoprecipitation products in H460 and BEAS-2B cells after circNOL10 silencing 
or overexpression, detected with western blot. F,H,I,P,R,T,U) n = 3, mean ± SD; unpaired t-test; compared with BEAS-2B, BEAS-2B NC or scramble 
group, *P < 0.05, **P < 0.01; compared with vec group, ##P < 0.01.
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Figure 5. Mechanism of transcriptional regulation of HN polypeptide family by SCML1. A) SCML1 protein domain analysis (http://smart.embl-
heidelberg.de) (Q9UN3 is an alias for SCML1). Monomer: 251–321 was a monomer of SCML1. B) KEGG analysis of SCML1 ChIP-Seq results. Cellular 
process, environmental information processing, human diseases, metabolism, and organismal systems are five aspects of KEGG analysis. Larger −log 
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cells (H460 and A549 cells) by overexpressing HN2 and HN8 
alone, silencing circNOL10 alone, and silencing circNOL10 
combined with overexpressing HN2 and HN8, respectively. 
Biomarkers indicating mitochondrial function, including reac-
tive oxygen species (ROS) (Figure 6B,C) and mitochondrial 
membrane potential (MMP), were detected with flow cytometry 
(Figure 6D,E), and by measuring total adenosine triphosphate 
(ATP) levels in the cells (Figure 6F). Silencing circNOL10 alone 
caused a significant decrease in ROS and significant increases 
in MMP and total ATP levels, while overexpressing HN2 and 
HN8 alone had the opposite effects. Silencing circNOL10 com-
bined with overexpressing HN2 and HN8 induced a more 
significant increase in ROS and decreases in MMP and total 
ATP level compared with overexpressing HN2 and HN8 alone. 
These results suggest that the HN family (HN2 and HN8) and 
circNOL10 can both modulate mitochondrial function in lung 
cancer cells, and circNOL10 may affect mitochondrial function 
by regulating the HN polypeptide family.
ROS are produced by aerobic metabolism, and can affect 
tumor cell apoptosis, proliferation, and cell cycle.[30,31] A 
decrease in MMP is a marker of the early stage of apoptosis,[32] 
while changes in ATP levels are associated with abnormal tumor 
cell behaviors, including cell viability and apoptosis.[33,34] We 
therefore investigated the effects of the HN polypeptide family 
(HN2, HN8) and circNOL10 on the biological processes and 
behaviors of H460 and A549 lung cancer cells overexpressing 
HN2 and HN8 alone, with silencing of circNOL10 alone, or 
with silencing of circNOL10 combined with overexpressing 
HN2 and HN8, respectively. We investigated cell viability with 
CCK8 assay (Figure 6G), apoptosis and cell cycle by flow cytom-
etry (Figure 6H–K and Figure S5A,B, Supporting Informa-
tion), and cell proliferation by (5-ethynyl-2′-deoxyuridine) (EdU) 
assay (Figure 6L,M). Silencing circNOL10 alone significantly 
increased cell viability and proliferation, decreased apoptosis, 
shortened G0/G1, and prolonged S phase and G2/M phase, 
while overexpressing HN2 and HN8 alone had the opposite 
effects. Compared with silencing circNOL10 alone, silencing 
circNOL10 combined with overexpressing HN2 and HN8 sig-
nificantly decreased cell viability and proliferation, increased 
cell apoptosis, prolonged G0/G1 phase, and shortened S and 
G2/M phases. Compared with overexpressing HN2 and HN8 
alone, the combined treatment had the opposite effects to those 
observed with silencing circNOL10 alone. These results indi-
cated that HN2 and HN8 could inhibit lung cancer cell viability, 
promote apoptosis, shorten S and G2/M phases, and inhibit 
cell proliferation, while the inhibitory effect of circNOL10 on 
lung cancer cell growth may be achieved through regulating the 
HN polypeptide family.
2.6. circNOL10 Altered Multiple Tumor Signaling Pathways  
by Regulating HN Polypeptide Family
We showed that circNOL10 altered biological processes such as 
apoptosis, proliferation, and cell cycle in tumor cells through 
regulating the HN polypeptide family. KEGG pathway analysis 
(http://www.kegg.jp/kegg/pathway.html) identified 16 tumor 
biomarkers involved in apoptosis, proliferation, and cell cycle 
progression. These biomarkers could be divided into two 
groups: group 1, including the apoptotic biomarkers POLE, 
MLH3, MSH2, LIG4, p53, and phospho-p53 (P-p53), of which 
POLE, MLH3, MSH2, and LIG4 are associated with DNA 
damage in apoptotic signal pathways; and group 2, including 
the proliferation and cell cycle biomarkers CKEK2, phospho-
CHEK2 (P-CHEK2), CDC25A, phospho-CDC25A (P-CDC25A), 
CCND1, CDK2, Rb, phospho-Rb (P-Rb), E2F1, and phospho-
E2F1 (P-E2F1).
We examined these 16 biomarkers in H460 and A549 cells 
with western blotting after silencing circNOL10 alone, over-
expressing HN2 and HN8 alone, or silencing circNOL10 
combined with overexpressing HN2 and HN8 (group 1: 
Figure 7A–D; group 2: Figure 7E–J). Silencing circNOL10 
alone decreased expression levels of ten biomarkers (POLE, 
MLH3, MSH2, p53, P-p53, CKEK2, P-CHEK2, P-CDC25A, 
Rb, and P-E2F1) and increased six (LIG4, CDC25A, CCND1, 
CDK2, P-Rb, and E2F1), while overexpressing HN2 and HN8 
had the opposite effects. Combined treatment increased the 
ten biomarkers and decreased the six compared with silencing 
circNOL10 alone, and had the opposite effects compared with 
overexpressing HN2 and HN8 alone.
We also investigated the effects of circNOL10 on the 16 
biomarkers in vivo. H460 cells transfected with circNOL10 
stably overexpressed vector (circNOL10 OE-ST) or blank vector 
(vec-ST) were injected subcutaneously into nude mice to 
form tumor xenografts and the 16 biomarkers were detected 
with immunohistochemistry (group 1: Figure 7K,L; group 2: 
Figure 7M,N). Ten markers (POLE, MLH3, MSH2, p53, P-p53, 
CKEK2, P-CHEK2, P-CDC25A, Rb, and P-E2F1) were increased 
and six (LIG4, CDC25A, CCND1, CDK2, P-Rb, and E2F1) were 
decreased in the circNOL10 OE-ST group compared with the 
vec-ST group. Detection of these 16 key molecules with western 
blot and immunohistochemistry confirmed that circNOL10 
inhibited the development of lung cancer by regulating the HN 
polypeptide family, involving alterations in multiple signaling 
pathways. The changes in these 16 tumor biomarkers associ-
ated with proliferation, cell cycle, and apoptosis were in line 
with the function of circNOL10 in inhibiting lung cancer devel-
opment through regulating the HN polypeptide family.
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(P value) indicates more significant enrichment and more differentially expressed genes (No. of genes). C) GO analysis of SCML1 ChIP-Seq results. 
Molecular function, cellular component, and biological process represent three aspects of GO analysis. Larger value of −log10 (P value) indicates more 
significant enrichment and more differentially expressed genes (No. of genes). D) Peaks of HN polypeptide family in ChIP-Seq plot. E–I) Detection 
of HN polypeptide family in SCML1 ChIP products (BEAS-2B, H460, and A549 cells) with PCR and qPCR. J,K) Detection of HN polypeptide family 
in circNOL10 ChIRP products (BEAS-2B, H460, and A549 cells) with PCR and qPCR. L,M) SCML1 motif sequences enriched in HN2/HN8 peaks. 
N–P) DNA EMSA. Probe, biotinylated circNOL10-specific EMSA probe; specific competitor, wild-type competitive probe; mutant competitor, mutant 
competitive probe; nuclear extraction, nuclear protein extract from H460 cells; antibody, SCML1- specific antibody. Q) HN2 and HN8 expression in 
H460 and A549 cells detected with qPCR after SCML1 silencing or overexpression. R) HN2 and HN8 expression in H460 and A549 cells detected with 
qPCR after circNOL10 silencing or overexpression. I,Q,R) n = 3, mean ± SD; unpaired t-test; **P < 0.01 compared with BEAS-2B or scramble group; 
##P < 0.01 compared with vec group.
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Figure 6. Function of circNOL10 in regulating HN polypeptide family in lung cancer cells. A) Mitochondria were stained using MitoTracker. HN2 and 
HN8 were labeled with Flag. Nuclei were stained with DAPI. Merge represents an overlay figure. B,C) ROS detection in H460 and A549 cells with FCM. 
FSC, forward scatter (proportional to cell size). D,E) Mitochondrial membrane potential in H460 and A549 cells detected with FCM. GRN-B-HLin (FL1) 
and RED-B-HLin (FL2) represent different channels in FCM assays. F) Relative ATP expression in H460 and A549 cells. G) Cell viability of H460 and 
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3. Discussion
Increasing numbers of circRNAs are being identified and their 
functions and molecular mechanisms elucidated. circRNAs 
have been shown to play important roles in various cancers. 
circRNA MYLK can act as an endogenous competitive RNA to 
promote the development of bladder cancer through regulating 
the vascular endothelial growth factor (VEGF)A/VEGF receptor 
2 signaling pathway.[35] circRNACCDC66 was shown to accelerate 
the proliferation and metastasis of colon cancer,[36] circLARP4 
regulated LARP4 expression by competitively binding to miR-
424-5p in gastric cancer,[37] and circLMO7 was involved in the 
regulation of myogenic differentiation in cattle.[38] circRNAs 
have also been shown to regulate the lung cancer phenotype by 
acting as endogenous competitive RNAs during carcinogenesis 
and tumor development[39,40]; however, studies on the function 
and mechanism of circRNAs in lung cancer are still limited. As 
natural endogenous RNAs, circRNAs have multiple functions 
associated with their specific structure, and further detailed 
studies are needed to explore their functions and molecular 
mechanisms.
In this study, we found that circNOL10 was downregu-
lated in lung cancer cells and in human lung cancer tissues. 
Analysis of clinical data showed significant differences in 
circNOL10 expression between lung adenocarcinoma and 
lung squamous cell carcinoma and in relation to the degree 
of differentiation. We predicted the function of circNOL10 by 
bioinformatics and indicated that the circRNA might play key 
roles in pathways related to the development of lung cancer. 
We therefore investigated the role of circNOL10 in cells in 
vitro and in a nude mouse model in vivo, and showed that 
circNOL10 downregulation significantly inhibited lung cancer. 
We further explored the reasons for circNOL10 downregula-
tion. RNA methylation is critical for the formation of mature 
RNAs,[21] and the formation of circRNAs is also regulated by 
splicing factors.[18] Results showed that splicing factor ESRP1 
promoted the expression of circNOL10 and NOL10 mRNA. 
Based on the results, we revealed that both RNA methylation 
and splicing factors were involved in the downregulation of 
circNOL10 in lung cancer cells.
circRNAs have diverse functions in cancer; in addition to 
functioning as endogenous competitive RNAs, some circRNAs 
encode proteins and are involved in tumors.[41] However, the 
role of circRNAs in transcriptional regulation in cancer remains 
unknown. High ubiquitination of proteins in the cell can pro-
mote their degradation, and increased protein expression is 
sometimes due to inhibition of ubiquitination.[23,24] The current 
study showed that circNOL10 enhanced SCML1 expression by 
inhibiting ubiquitination of the transcription factor SCML1. 
Furthermore, ChIP-Seq and molecular experiments revealed 
that SCML1 regulated transcription of the HN polypeptide 
family, while circNOL10 affected HN expression by regulating 
SCML1. The HN polypeptide family has a protective function 
in normal cells.[26,27] The HN peptide family has high homology 
with the mitochondrial genome, but the specific source has not 
yet been finalized.[27] HN polypeptide family members (HN2, 
HN8) are located in mitochondria, and it is therefore important 
to clarify the effects of HN2 and HN8 on mitochondrial func-
tion. We found that two members of the HN family, HN2 and 
HN8, were located in the mitochondria. The mitochondria are 
responsible for cellular energy metabolism, and abnormalities 
in mitochondrial function also contribute to tumor develop-
ment.[29,30] We detected biomarkers of mitochondrial function 
and key molecules involved in proliferation, apoptosis, and cell 
cycle signaling pathways, and showed that circNOL10 inhib-
ited cell proliferation and cell cycle progression, and promoted 
apoptosis in lung cancer cells. These effects may be achieved by 
promoting SCML1 and further regulating transcription of the 
HN polypeptide family. In this study, we found that circNOL10 
regulated multiple tumor signaling pathways in the regulation 
of the HN polypeptide family, by detecting a variety of tumor 
signaling pathway molecules.
The results of this study provide new insights into the 
role of circRNAs in lung cancer, and provide evidence for the 
molecular mechanisms whereby circRNAs participate in tran-
scriptional regulation. Furthermore, we showed that circNOL10 
inhibited lung cancer by enhancing transcriptional regulation 
of the HN polypeptide family by SCML1. These findings fur-
ther our understanding of lung cancer and may help to identify 
new diagnostic and therapeutic targets. This study revealed that 
circNOL10 was significantly downregulated in lung cancer and 
was involved in lung cancer inhibition. circNOL10 downregula-
tion in lung cancer cells was co-regulated by Pre-NOL10 meth-
ylation and the splicing factor ESRP1. Furthermore, circNOL10 
promoted expression of the transcription factor SCML1 and 
further induced transcription of the HN polypeptide family in 
lung cancer. Members of the HN polypeptide family can be 
transferred into mitochondria to affect mitochondrial func-
tion and key biological processes such as apoptosis, prolifera-
tion, and cell cycle progression in lung cancer cells, which may 
be mediated by multiple signaling pathways (Figure 7O and 
Figure S6, Supporting Information).
4. Experimental Section
Cell and Animal Experiments and Human Tissue Samples: The cells 
used in this study were all cultured as recommended by the American 
Type Culture Collection. All cell lines were authenticated by short 
tandem repeat profiling. All the animal experiments in this study were 
approved by the Experimental Animal Ethics Committee of Guangzhou 
Medical University. The experimental animals were maintained under 
specific-pathogen-free conditions at the Experimental Animal Center of 
Guangzhou Medical University, and fed in accordance with the rules of 
the center. The BALB/c-nu/nu mice used in this study were provided 
by the Guangdong Medical Laboratory Animal Center. Human tissue 
samples were provided by the tissue bank of the Institute of Chemical 
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A549 cells detected with CCK8 assay. H,I) Apoptosis of H460 and A549 cells detected with FCM. AnnexinV-FITC and PI were used to indicate apop-
tosis. J,K) Cell cycle in H460 and A549 cells detected with FCM. Cells stained with PI. Cell count, the number of cells in different cell cycle phases. L,M) 
Proliferation of H460 and A549 cells detected with EdU assay. Nuclei were stained with DAPI. EdU indicates proliferating cells. C,E,F,G,I,K,M) n = 3, 
mean ± SD; unpaired t-tests used for comparisons between treatment and control groups (vec or scramble), *P < 0.05, **P < 0.01; ANOVA used for 
comparisons between different treatment groups, #P < 0.05, ##P < 0.01.
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Figure 7. Detection of molecules potentially associated with circNOL10-regulated inhibitory effect of HN polypeptide family on lung cancer develop-
ment. A–D) Semi-quantitative analysis of POLE, MLH3, MSH2, LIG4, p53, and P-p53 protein expression in H460 and A549 cells, detected with western 
blot. E–J) Semi-quantitative analysis of CHEK2, P-CHEK2, CDC25A, P-CDC25A, CCND1, CDK2, Rb, P-Rb, E2F1, and P-E2F1 protein expression in H460 
and A549 cells, detected with western blot. K,L) Quantitative analysis of POLE, MLH3, MSH2, LIG4, p53, and P-p53 protein expression in subcutaneous 
tumors in nude mice (circNOL10 overexpression and control) detected by immunohistochemistry. M,N) Quantitative analysis of CHEK2, P-CHEK2, 
CDC25A, P-CDC25A, CCND1, CDK2, Rb, P-Rb, E2F1, and P-E2F1 protein expression in subcutaneous tumors in nude mice (circNOL10 overexpression 
and control), detected by immunohistochemistry. O) Mechanism of circNOL10 in inhibiting lung cancer.
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Carcinogenesis of Guangzhou Medical University, from individuals 
from Guangzhou City. Informed consent was obtained from all patients 
before sample collection. This study was approved by the Medical Ethics 
Committee of Guangzhou Medical University.
High-Throughput Sequencing and Protein MS: High-throughput 
ChIP-Seq was performed with RAP-MS and pull-down MS. Sequencing 
results and protein MS results are listed in the Supporting 
Information.
Statistical Analysis: The experimental data were analyzed using SPSS 
17.0 software (SPSS Inc., Chicago, IL, USA). The data were expressed 
as mean ± SD, based on n = 3. The data were analyzed using paired 
or unpaired t-tests or ANOVA, as appropriate. A P value of <0.05 was 
considered statically significant.
“Detailed methods are described in the Supporting Information.”
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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